Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 5/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4003305 | 0.82 | CYP11B1 (0.44) | CYP11B1CYP11B2NOS1CYP19A1CYP3A4 | |
| SCHEMBL1698952 | 0.82 | CYP11B1 (0.39) | CYP11B1CYP11B2NOS1CYP3A4CYP2D6 | |
| SCHEMBL2359179 | 0.81 | NOS1 (0.52) | CYP11B1CYP11B2HSP90AA1HSP90AB1NOS1 | |
| SCHEMBL16100223 | 0.79 | CYP11B2 (0.61) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL14243162 | 0.79 | CYP11B1 (0.43) | CYP11B1CYP11B2NOS1CYP3A4CYP2D6 | |
| SCHEMBL24013546 | 0.74 | CYP11B1 (0.36) | CYP11B1CYP11B2HSP90AA1HSP90AB1 | |
| SCHEMBL899423 | 0.74 | CYP11B2 (0.35) | CYP11B1CYP11B2NOS1 | |
| SCHEMBL27399063 | 0.71 | KDM4E (0.41) | CYP11B1CYP11B2HSP90AA1HSP90AB1HCAR1 | |
| SCHEMBL14109842 | 0.70 | TDP1 (0.43) | HSP90AA1HSP90AB1HCAR1ABCB1LMNA | |
| SCHEMBL6601220 | 0.70 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP19A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| CN-1731994-A | Prophylactic and therapeutic agent for neuropathy | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | CYP11B1 377/4885CYP11B2 90/4885HSP90AA1 2751/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | CYP11B1 377/4885CYP11B2 90/4885HSP90AA1 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.